Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Feb;61(2):319–322. doi: 10.1038/bjc.1990.61

High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study.

J W Sweetenham 1, J J McKendrick 1, D H Jones 1, J M Whitehouse 1, C J Williams 1
PMCID: PMC1971386  PMID: 2155645

Abstract

Retrospective studies have recently demonstrated a significant correlation between dose intensity of chemotherapy and response rates and survival in various diseases including epithelial ovarian carcinoma. As part of a proposed randomised trial to assess the effect of dose intensity on outcome in ovarian carcinoma, a pilot study has been undertaken to determine the toxicity and efficacy of the high intensity therapy. Nineteen patients with advanced ovarian carcinoma received initial treatment with cisplatin 120 mg m-2 i.v. day 1, and cyclophosphamide 1,000 mg-2 i.v. day 1, given at 21-day intervals for six cycles. The average relative dose intensity of this therapy is 1.14 when compared with the CHAP regimen. Severe toxicity was experienced by most patients. The median received average relative dose intensity was 0.90, with only one patient receiving treatment to the proposed intensity. Randomised studies of the effect of dose intensity in ovarian carcinoma are essential, but an initial step must be to assess whether the proposed high dose treatment can be delivered.

Full text

PDF
319

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barker G. H., Wiltshaw E. Randomised trial comparing low-dose cisplatin and chlorambucil with low-dose cisplatin, chlorambucil, and doxorubicin in advanced ovarian carcinoma. Lancet. 1981 Apr 4;1(8223):747–750. doi: 10.1016/s0140-6736(81)92625-8. [DOI] [PubMed] [Google Scholar]
  2. Bronchud M. H., Scarffe J. H., Thatcher N., Crowther D., Souza L. M., Alton N. K., Testa N. G., Dexter T. M. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987 Dec;56(6):809–813. doi: 10.1038/bjc.1987.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bruckner H. W., Cohen C. J., Goldberg J. D., Kabakow B., Wallach R. C., Deppe G., Greenspan E. M., Gusberg S. B., Holland J. F. Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin. Cancer. 1981 May 1;47(9):2288–2294. doi: 10.1002/1097-0142(19810501)47:9<2288::aid-cncr2820470931>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  4. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  5. Decker D. G., Fleming T. R., Malkasian G. D., Jr, Webb M. J., Jeffries J. A., Edmonson J. H. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol. 1982 Oct;60(4):481–487. [PubMed] [Google Scholar]
  6. Hryniuk W. M. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol. 1987 Mar;14(1):65–74. [PubMed] [Google Scholar]
  7. Hryniuk W., Levine M. N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986 Aug;4(8):1162–1170. doi: 10.1200/JCO.1986.4.8.1162. [DOI] [PubMed] [Google Scholar]
  8. Jacobs A. J., Sommers G. M., Homan S. M., Camel H. M., Axelrod J. H., Kao M. S., Galakatos A. E., Parham J., Lippmann L. Therapy of ovarian carcinoma: the relationship of dose level and treatment intensity to survival. Gynecol Oncol. 1988 Sep;31(1):233–247. doi: 10.1016/0090-8258(88)90300-9. [DOI] [PubMed] [Google Scholar]
  9. Levin L., Hryniuk W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987 May;5(5):756–767. doi: 10.1200/JCO.1987.5.5.756. [DOI] [PubMed] [Google Scholar]
  10. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Willemse P. H., Heintz A. P., van Lent M., Trimbos J. B., Bouma J., Vermorken J. B. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol. 1987 Aug;5(8):1157–1168. doi: 10.1200/JCO.1987.5.8.1157. [DOI] [PubMed] [Google Scholar]
  11. O'Connell G., Shelley W., Carmichael J., Fraser R., Kirk M. E., Krepart G., Levin L., Swenerton K. High-dose-intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian carcinoma. Cancer Treat Rep. 1987 May;71(5):455–458. [PubMed] [Google Scholar]
  12. Ozols R. F., Ostchega Y., Myers C. E., Young R. C. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol. 1985 Sep;3(9):1246–1250. doi: 10.1200/JCO.1985.3.9.1246. [DOI] [PubMed] [Google Scholar]
  13. Williams C. J., Mead G. M., Macbeth F. R., Thompson J., Whitehouse J. M., MacDonald H., Harvey V. J., Slevin M. L., Lister T. A., Shepherd J. H. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol. 1985 Nov;3(11):1455–1462. doi: 10.1200/JCO.1985.3.11.1455. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES